Page 217 of 286 · 8,574 total

patent null

Nintendo Co., Ltd. et al. v.American GNC Corporation

· IPR2024-00667

Nintendo challenges American GNC's angular rate sensor patent (6508122), arguing the claims are obvious over various prior art combinations. The petitioner asserts that combining references like Fujiyoshi with Townsend or Cox renders the claimed technology predictable in the field of MEMS sensors.

patent null

Roku, Inc. v.Intent IQ, LLC

· IPR2024-00666

Roku challenges Intent IQ's patent 10715878 in a Petition, arguing that the claims are obvious under 35 U.S.C. § 103. The petitioner relies on multiple prior art references (Baig, Laidlaw, Sitaraman, Hahn, Xu, Gerace) to establish obviousness across various technical features related to targeted advertising and cross-device tracking.

patent null

FERVO ENERGY CO. v.Ormat Technologies, Inc.

· IPR2024-00665

FERVO ENERGY CO. challenges Ormat Technologies' patent (7320221) in a PTAB petition, asserting obviousness over multiple combinations of geothermal and hydrocarbon prior art. The petitioner argues that the challenged claims are unpatentable under 35 U.S.C. § 103 based on references including Rinaldi, Mims, and Swenson.

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00650

Merck Sharp & Dohme LLC petitioned to invalidate U.S. Patent No. 11,634,491 on grounds of anticipation and obviousness in the field of Oncology/Immunotherapy. The petitioner argues that key claims are anticipated by the MSI-H Study Record (EX1005) under 35 U.S.C. § 102. Furthermore, the remaining claims are deemed obvious when combining the MSI-H Study Record with various prior art references like Brown, Duval, Benson, and Koh under 35 U.S.C. § 103.

patent null

Databricks, Inc. v.R2 Solutions LLC

· IPR2024-00659

Databricks, Inc. challenges R2 Solutions LLC's patent (8,190,610) in a Petition proceeding, arguing that the claimed enhancements to MapReduce are obvious. The petitioner contends that combining existing distributed processing techniques from Pike and Chowdhuri renders the claims predictable to a Person Having Ordinary Skill in the Art.

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00649

Merck Sharp & Dohme LLC challenges U.S. Patent No. 11,629,187 in an IPR proceeding before the PTAB. The petitioner argues that all claims are unpatentable under both anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00648

Merck Sharp & Dohme LLC challenged U.S. Patent No. 11,643,462 in the PTAB, arguing that all claims are anticipated under 35 U.S.C. § 102 and rendered obvious under 35 U.S.C. § 103. The petitioner asserts that the MSI-H Study Record discloses the claimed method of treating MSI-H cancer with pembrolizumab, leading to a request for institution based on compelling evidence.

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00647

Merck Sharp & Dohme LLC challenges The Johns Hopkins University's patent (11,649,287) in an IPR proceeding based on anticipation and obviousness. Petitioner asserts that the MSI-H Study Record discloses all claimed methods, rendering the claims unpatentable under 35 U.S.C. § 102 and § 103. The petitioner argues for discretionary denial of institution is inappropriate given the prior art's relevance to the patent's scope.

patent null

Aptiv Services US, LLC et al. v.Microchip Technology, Inc.

· IPR2024-00646

Aptiv Services challenged Microchip Technology's LDO voltage regulator patent (9471074), arguing that the claimed features are obvious over prior art. The petitioner relies heavily on combinations of references like Al-Shyoukh, Rincon-Mora, Ivanov, and Stanescu to demonstrate lack of inventive step.

patent instituted

Capital One, National Association et al. v.--

· IPR2024-00643

Capital One National Association filed an IPR challenging Implicit, LLC's patent 8056075 on grounds of obviousness (35 U.S.C. §103). The petition asserts that the claims are rendered unpatentable by various combinations of prior art references including Fowlow and Kimera.

patent null

AT&T Corp et al. v.Daingean Technologies Ltd.

· IPR2024-00644

AT&T and its partners filed a Petition challenging Daingean Technologies' '400 Patent, asserting that claims 5, 7, and 8 are anticipated or obvious by the prior art reference R2-1702708. The challenge focuses on dual-connectivity/5G standards, arguing that an Ericsson technical contribution discloses all elements of the challenged claims. This is a critical early stage attack in ongoing litigation against Daingean Technologies.

patent null

Loco Crazy Good Cookers, Inc. v.North Atlantic Imports, LLC

· IPR2024-00642

Loco Crazy Good Cookers challenges the validity of North Atlantic Imports' griddle patent (10660473), asserting that core features are obvious in light of prior art. The petitioner relies on multiple combinations of references, including Williams and May/Best, to invalidate numerous claims under 35 U.S.C. § 103.

patent instituted

Under Armour, Inc. v.Athalonz, LLC

· IPR2024-00640

Under Armour challenged Athalonz's athletic shoe sole patent via IPR, asserting obviousness based on combinations of prior art references like Won and Norton. The Board decided to institute the proceeding, finding that factors weighed against discretionary denial despite the complexity of the technical arguments.

patent instituted

Under Armour, Inc. v.Athalonz, LLC

· IPR2024-00639

Under Armour filed an IPR challenging the validity of Athalonz's athletic shoe patent (11375768). The petition asserts that various claimed features, including a gradient compression forefoot platform and uniform heel height, are obvious based on combinations of prior art.

patent instituted

Under Armour, Inc. v.Athalonz, LLC

· IPR2024-00638

Under Armour challenges Athalonz's athletic footwear patent (11064760) in an IPR petition, asserting that all 11 claims are obvious over multiple prior art references. The petitioner argues the claimed features were conventional knowledge in the field of athletic positioning footwear.

patent instituted

Under Armour, Inc. v.Athalonz, LLC

· IPR2024-00636

Under Armour challenged Athalonz's '786 patent for athletic/golf footwear sole design via an IPR petition. The petitioner argued that all eight claimed features were obvious based on prior art references including Kim, Dufour, and Rubin. The Board subsequently instituted the proceeding.

patent instituted

Under Armour, Inc. v.Athalonz, LLC

· IPR2024-00637

Under Armour challenged Athalonz's athletic footwear patent (US 11013291) in an IPR, arguing the claims are obvious over prior art including Kim, Dufour, and Rubin. The PTAB has instituted the proceeding, finding merit in the challenger's arguments against discretionary denial.

patent instituted

Fluidmaster, Inc. v.Danco, Inc. et al.

· IPR2024-00635

Fluidmaster challenged Danco's patent covering toilet/bowl fill valve connections, arguing the claims are obvious under 35 U.S.C. §103. The PTAB institution decision found that the claimed quick connector features were predictable based on various prior art references.

patent null

Fluidmaster, Inc. v.Danco, Inc. et al.

· IPR2024-00634

Fluidmaster challenges the validity of a toilet fill valve patent (9103105) by asserting anticipation and obviousness. The petitioner argues that various combinations of prior art, including Guoxin in view of Ho and Schuster, render all 24 claims invalid. This petition is filed during concurrent litigation with Danco, Inc.

patent null

Fluidmaster, Inc. v.Danco, Inc. et al.

· IPR2024-00633

Fluidmaster challenges the validity of a patent covering water flow regulation in plumbing fixtures, asserting that the claims are anticipated by Schuster and rendered obvious over multiple combinations of prior art references. The petition focuses heavily on 35 U.S.C. §102 (Anticipation) and §103 (Obviousness).

patent null

TESLA, INC. v.iQar Inc.

· IPR2024-00630

Tesla challenges iQar Inc.'s patent (10850616) in a PTAB petition, asserting that the claims are anticipated or obvious over prior art references like Koebler650. The petitioner argues that combining existing technologies to improve vehicle power management was predictable for a POSITA.

patent null

Amazon.com, Inc. et al. v.Nokia Technologies Oy

· IPR2024-00627

Amazon challenges Nokia's video coding patent (11805267), arguing that the claimed weighted bi-directional motion prediction is anticipated by prior art. The petitioner relies heavily on Karczewicz references to demonstrate that using higher precision for intermediate calculations was already known in the field.

patent denied

Amazon.com, Inc. et al. v.Nokia Technologies Oy

· IPR2024-00626

Amazon challenged Nokia's video coding patent (11805267) before the PTAB, arguing that the claimed methods are obvious over prior art references. The Board denied the petition, finding no basis for discretionary denial under §325(d).

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00625

Merck Sharp & Dohme LLC challenges the validity of JHU's patent (11,339,219) in an IPR petition. The petitioner asserts that all eight claims are anticipated by or obvious over prior art, primarily citing the MSI-H Study Record and various combinations thereof. This petition seeks to invalidate the core claims related to treating MSI-H tumors with pembrolizumab.

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00624

Merck Sharp & Dohme LLC challenged The Johns Hopkins University's patent (11325975) in a Petition, arguing all claims are anticipated by the MSI-H Study Record and rendered obvious by combinations of prior art. The petitioner asserts that the study record inherently discloses every limitation of the claimed method for treating MSI-H patients with anti-PD-1 antibodies.

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00623

Merck Sharp & Dohme LLC challenges The Johns Hopkins University's patent (11325974) in an IPR, arguing that all claims are unpatentable. Petitioner asserts the MSI-H Study Record anticipates the claims under 35 U.S.C. § 102 and various prior art combinations render them obvious under § 103.

patent null

Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University

· IPR2024-00622

Merck Sharp & Dohme LLC challenged The Johns Hopkins University's patent (10934356) in an IPR, asserting that all claims are anticipated or obvious. Petitioner relies heavily on the MSI-H Study Record and various prior art references to demonstrate invalidity across multiple grounds. This petition sets up a significant challenge to the scope of PD-1 inhibitor patents for MSI-H cancers.

patent null

Mito Red Light, Inc. v.Joovv, Inc.

· IPR2024-00621

Mito Red Light, Inc. challenged Joovv, Inc.'s patent (11253719) in the PTAB, arguing that the claims are obvious under 35 U.S.C. § 103. The petitioner relies heavily on prior art references including Dijkstra and Norwood to demonstrate obviousness in photobiomodulation therapy systems.

patent null

Mianyang BOE Optoelectronics Technology Co., Ltd. et al. v.Samsung Display Co., Ltd.

· IPR2024-00620

The Petitioner challenges claims of the '9330593 patent using multiple obviousness grounds against various prior art references, including Kimura and Shin/Sasaki. The petition requests institution, arguing that co-pending litigation does not warrant discretionary denial.

patent instituted

Teladoc Health, Inc. v.Data Health Partners, Inc.

· IPR2024-00618

Teladoc Health, Inc. challenged Data Health Partners, Inc.'s '812 Patent in an IPR proceeding, arguing the system for tracking client progress was obvious over various combinations of prior art. The PTAB determined that institution is appropriate, allowing the challenger to proceed with its grounds of obviousness (103).

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →